Results of a phase 2 dose-ranging and safety extension study of a novel oral fumarate, bg-12, in patients with severe psoriasis

被引：0
|
作者：
Langncr, A
Spellman, MC
机构：
[1] Med Univ Warsaw, Warsaw, Poland
[2] Biogen Idec Inc, San Diego, CA USA
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2005年 / 52卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：P193 / P193
页数：1
相关论文
共 50 条
  • [1] Efficacy and safety of a novel formulation of an oral fumarate, BG-12, in patients with moderate to severe plaque psoriasis: Results of a phase III study
    Mrowietz, U
    Spellman, MC
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2005, 52 (03) : P182 - P182
  • [2] Safety and Tolerability of Oral BG-12 (Dimethyl Fumarate) in Relapsing-Remitting Multiple Sclerosis (RRMS): Interim Results from ENDORSE Extension Study
    Phillips, J. Theodore
    Fox, Robert
    Selmaj, Krzysztof
    Raghupathi, Kartik
    Yuan, Huixing
    Novas, Mark
    Sweetser, Marianne
    Viglietta, Vissia
    Dawson, Katherine
    Gold, Ralf
    NEUROLOGY, 2013, 80
  • [3] Efficacy and safety of etrasimod in Japanese UC patients: results of a phase 2 dose-ranging study
    Takeuchi, K.
    Nakase, H.
    Hisamatsu, T.
    Matsuoka, K.
    Arai, S.
    Yuasa, H.
    Oe, M.
    Ono, R.
    Keating, M.
    Gu, G.
    Lazin, K.
    Mcdonnell, A.
    Fokuta, K.
    Hibi, T.
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : i1183 - i1185
  • [4] Efficacy and safety of oral sarecycline for the treatment of moderate to severe facial acne vulgaris: Results of a phase 2, dose-ranging trial
    Leyden, James J.
    Sniukiene, Vilma
    Berk, David R.
    Kaoukhov, Alexandre
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 76 (06) : AB113 - AB113
  • [5] Safety profile of BG-12 (dimethyl fumarate) in relapsing remitting multiple sclerosis: long-term interim results from the ENDORSE extension study
    Phillips, J. T.
    Fox, R. J.
    Selmaj, K.
    Yang, M.
    Zhang, R.
    Novas, M.
    Sweetser, M. T.
    Viglietta, V.
    Gold, R.
    MULTIPLE SCLEROSIS JOURNAL, 2013, 19 (11) : 457 - 457
  • [6] Safety and tolerability of BG-12 in patients with relapsing-remitting multiple sclerosis: results from the phase 3 CONFIRM (Comparator and an Oral Fumarate in Relapsing-Remitting Multiple Sclerosis) study
    Havrdova, E.
    Phillips, J. T.
    Fox, R. J.
    Miller, D.
    Kita, M.
    Hutchinson, M.
    Raghupathi, K.
    Yuan, H.
    Novas, M.
    Sweetser, M. T.
    Viglietta, V.
    Dawson, K. T.
    JOURNAL OF NEUROLOGY, 2012, 259 : S105 - S105
  • [7] Efficacy and Safety of BG-12 (Dimethyl Fumarate) in Relapsing-Remitting Multiple Sclerosis in the Phase 3 CONFIRM Study
    Hutchinson, M.
    Fox, R. J.
    Phillips, J. T.
    Miller, D. H.
    Havrdova, E.
    Kita, M.
    Yang, M.
    Zhang, R.
    Novas, M.
    Sweetser, M. T.
    Viglietta, V.
    Dawson, K. T.
    MULTIPLE SCLEROSIS JOURNAL, 2013, 19 (05) : 683 - 683
  • [8] Efficacy, safety, and quality of life effects of a novel oral formulation of dimethyl fumarate in patients with moderate to severe plaque psoriasis: Results of a phase 3 study
    Mrowieta, U
    Reich, K
    Spellman, MC
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2006, 54 (03) : AB202 - AB202
  • [9] Secukinumab efficacy and safety outcomes from a phase II subcutaneous dose-ranging study in the treatment of moderate to severe plaque psoriasis
    Papp, K.
    Sigurgeirsson, B.
    Papavassilis, C.
    Richards, H. B.
    Haemmerle, S.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2012, 66 (04) : AB203 - AB203
  • [10] Safety and tolerability results of a phase 2b extension study of the novel oral fumarate BG00012 for the treatment of relapsing-remitting multiple sclerosis
    Kappos, Ludwig
    Gold, Ralf
    Miller, David
    MacManus, David G.
    Havrdova, Eva
    Limmroth, Volker
    Polman, Chris
    Schmierer, Klaus
    Yousry, Tarek
    Yang, Minhua
    Eraksoy, Mefkure
    Meluzinova, Eva
    Rektor, Ivan
    O'Neill, Gilmore
    NEUROLOGY, 2007, 68 (12) : A276 - A277
12345